ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / SLN / options
SNDX (17) OPK (40) RAPP (30) VSTM (36) ⌘ Pro Terminal β†’

Silence Therapeutics Plc American Depository Share (SLN) Options Positioning, Max Pain & Unusual Sweeps

$19.76 +0.05% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.72

Silence Therapeutics Plc American Depository Share (SLN) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $1.23B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Silence Therapeutics Plc American Depository Share (NASDAQ: SLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $19.76 (+0.05% 1D, market cap $1.23B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SLN ranks #384 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SLN compare to SNDX and OPK in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 61.5%, and ROIC of -35.0%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, SLN leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLN?
β–Ό

Per SLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479615), Silence Therapeutics Plc American Depository Share generated $559.0K in revenue (-98.7% YoY), -$88.6M in net income, and -$62.3M in free cash flow against $131.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.72 (-0.18%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 9/20 (D) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (44/100 Β· D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510044
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D Β· Rk D-
Cash (9)Whales (16)SEC (7)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$22 Bull$19 Base$14 Bear
πŸ“¬ FREE SLN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SLN)Realized 20D OHLCV Swing Band: Β±6.9%
Deterministic 5-Pillar Attribution (44/100 Composite)
πŸ” WHY SLN SCORES 44/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (36% of score)

20D Institutional Volume Accumulation (Β±6.9% realized swing band)

β–² #2 Bullish Driver: Cash Engine Quality+9/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 34.4% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
36
Grade E$8.87+121.1% Next Q
Q2 (-2Q)
39
Grade E$19.61+0.9% Next Q
Q3 (-1Q)
41
Grade D$19.78-0.1% Next Q
Current
44
Grade D$19.76-6.5% Hist 90D Ξ±
Trajectory: E (36) β†’ D (44)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SLN Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SLN currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.74) and Max Pain ($20.75) forces dealer call-delta covering toward $21.85.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSLN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±6.9%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SLN)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SLN.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLN)

  • βœ“Walkthrough of SLN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +171.06%⚑ TESTING RESISTANCE
2026-11-03O $19.80H $19.80L $19.75C $19.76VOL 621.4K
RES: $20.11SUP: $8.62SMA50: $13.74SMA200: $9.20
$20.85$16.75$12.66$8.56$4.47RES $20.11SUP $8.62$19.762026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SLN Butterfly Map β†’ + Track SLN β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -98.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SLN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SLN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLN)

Health Care Rank #384 of 1015 βš”οΈ SNDX vs SLN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SLN vs. SNDX, OPK, RAPP, VSTM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Silence Therapeutics Plc American Depository Share (SLN) ranks #384 by composite RQD confidence (44/100, grade D) and #329 by equity capitalization ($1.23B). Within this direct 5-issuer industry benchmark cohort, SLN leads on earnings valuation at N/A trailing P/E, while OPK leads on capital efficiency and profitability with -10.2% ROIC and 33.9% gross margin. SLN currently leads its immediate peer cohort in composite quantitative strength at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SLN ACTIVE
Silence Therapeutics Plc American Depository Share
D 44/100 β€” 61.5% -35.0% +0.05% $1.23B Benchmark Subject
SNDX
Syndax Pharmaceuticals Inc.
E 17/100 β€” β€” -35.0% -4.03% $1.22B /sndx-vs-sln β†’
OPK
OPKO Health Inc.
D- 40/100 β€” 33.9% -10.2% +3.61% $1.24B /opk-vs-sln β†’
RAPP
Rapport Therapeutics Inc.
E 30/100 β€” β€” -22.9% +0.32% $1.20B /rapp-vs-sln β†’
VSTM
Verastem Inc.
D- 36/100 β€” β€” -35.0% -1.64% $1.18B /vstm-vs-sln β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001479615 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Silence Therapeutics Plc American Depository Share (SLN) reported GAAP revenue of $559.0K (-98.7% vs. FY2024 revenue of $43.3M , and -98.2% cumulative change since FY2023) , GAAP net income of -$88.6M, operating cash flow of -$62.3M, and free cash flow of -$62.3M (+8.1% YoY). On the balance sheet, SLN closed FY2025 with $131.4M in total assets against $0 in total debt (Altman Z-Score: 3.36, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $559.0K -$88.6M -$62.3M -$62.3M $131.4M β€”
FY2024 (FY) 2024-12-31 $43.3M -$45.3M -$67.6M -$67.9M $202.6M β€”
FY2023 (FY) 2023-12-31 $31.6M -$54.2M -$49.5M -$49.5M β€” β€”

3. SLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Silence Therapeutics Plc American Depository Share (NASDAQ: SLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $19.76 (+0.05% 1D, market cap $1.23B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SLN ranks #384 in composite RQD confidence.

How does SLN compare to SNDX and OPK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 61.5%, and ROIC of -35.0%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and OPK (OPKO Health Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B). Among the 5-stock peer group, SLN leads on earnings multiple (N/A) while OPK leads on capital efficiency (-10.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLN?

Per SLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479615), Silence Therapeutics Plc American Depository Share generated $559.0K in revenue (-98.7% YoY), -$88.6M in net income, and -$62.3M in free cash flow against $131.4M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLN trading relative to its 50-day, 200-day, and 52-week technical levels?

SLN last traded at $19.76 (+0.05% on volume of 1,186,323 shares), positioning the stock +43.81% above its 50-day simple moving average ($13.74) and +114.78% above its 200-day simple moving average ($9.20). Across its 52-week range of $4.19 to $19.86, SLN sits at the 99.4% percentile with a 14-day RSI of 78.5 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±6.9% ($18.40 to $21.12).

Direct Sub-Reports: SLN RQD Cockpit SLN 12M Forecast SLN Earnings & Move SLN Dividends & DRIP SLN Insiders & 13F SLN Whale Options SLN Profit Sankey SLN News & Why
ROARABLE RATING BRIEF β€’ RQD 44/100 (D) βœ“ SEC XBRL & RQD VERIFIED

SLN β€” Silence Therapeutics Plc American Depository Share: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Silence Therapeutics Plc American Depository Share (SLN) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $19.76 (+0.05% 1D, market capitalization $1.23B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 61.5%, operating margin of -60.0%, and free cash flow yield of -5.06%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.36, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Its market capitalization is $1.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Silence Therapeutics Plc American Depository Share (SLN) reported $559.0K in annual revenue (up from $43.3M in FY2024, -98.7% YoY) and -$88.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.6M revenue, -$54.2M net income) through FY2025, SLN scaled operating cash flow to -$62.3M and free cash flow to -$62.3M, backed by $131.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 44/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -5.06% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $4.19 – $19.86 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Can SLN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $559.0K and free cash flow of -$62.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SLN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SLN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Silence Therapeutics Plc American Depository Share (SLN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SLN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLN Bull vs. Bear Conversation Board β€” What's Your Call at $19.76?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SLN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $24.49 (+24.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning earn the highest RQD pillar score (16/20), indicating relative strength in whale-flo

Here is why I am bullish on SLN here at $19.75: Institutional accumulation and options positioning earn the highest RQD pillar score (16/20), indicating relative strength in whale-flow signals.. Compare SLN's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $18.76 are getting bought.

RetailWhale_TX πŸ‚ BULL

@SkepticalCFA Shorting a 16/20 institutional whale-flow stock at $19.75 is dangerous when funds are rotating into Health Care.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $16.39 (-17.0%)
Spot @ $19.75

A -35% ROIC, -5.06% FCF yield, and an FY 2025 cash balance of $11.3M against -$62.3M free cash flow point to weak cash generation and l

A -35% ROIC, -5.06% FCF yield, and an FY 2025 cash balance of $11.3M against -$62.3M free cash flow point to weak cash generation and limited runway.. Look at the math on SLN: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $17.38 before getting long.

LIVE TAPE